All episodes

In this podcast, Xiuning Le from the University of Texas MD Anderson Cancer Center, Houston, TX, Eric Nadler from the Baylor University Medical Center, Dallas, TX, Daniel Costa from the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, and John Heymach from the University of Texas MD Anderson Cancer Center, Houston, TX discuss the use of EGFR tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer harboring uncommon EGFR mutations. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology...

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-023-02664-1. All conflicts of interest can be found online.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made....

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: Expert Discussion on Challenges in C3G Diagnosis: A Podcast Article on Best Practices in Kidney Biopsies | Advances in Therapy (springer.com). All conflicts of interest can be found online.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to...

In this podcast, two oncologists and two patient advocates from the patient advocacy group EGFR Resisters talk about the importance of biomarker testing for patients with non-small cell lung cancer and how this can affect treatment decisions and personalised medicine. The panel discusses what biomarkers are, the processes involved in obtaining biomarker testing, how biomarker information is used, and the importance of waiting for biomarker results prior to determining treatment. The panel also discusses patient perspectives on biopsy and biomarker testing and how healthcare professionals can best help guide new patients through this process.  This podcast is published open access...

  This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: Uterine Fibroids: A Podcast on Patient and Physician Perspectives on Medical Management and a New Medical Therapy (Relugolix Combination Therapy) | Advances in Therapy (springer.com). All conflicts of interest can be found online.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as...

In this podcast, a healthcare professional discusses germline genetic testing with a patient advocate and answers questions regarding the importance of testing in patients with metastatic breast cancer, with a specific focus on germline or inherited breast cancer susceptibility gene (BRCA) mutations. In the USA, national guidelines recommend that all patients with recurrent or metastatic breast cancer should be offered genetic testing for germline breast cancer susceptibility gene 1 or 2 (BRCA1 or 2) mutations to identify patients potentially suitable for treatment with a poly(ADP-ribose) polymerase inhibitor.  The aim of this podcast is to provide physicians with information to support the early...

Brain metastases are especially common in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with a cumulative incidence of over 50% and associated with a poor prognosis, high symptom burden, and decreased quality of life. In this podcast, authors discuss the clinical significance of controlling the onset of brain metastases, considerations in selecting a first-line therapy option, efficacy and safety observed in patients with and without brain metastases, and rationales for using lorlatinib upfront versus reserving for a later line in therapy.   This podcast is published open access in Advances in Therapy and is fully citeable. You can...

This podcast is published open access in Neurology and Therapy and is fully citeable. You can access the original published podcast article through the Neurology and Therapy website and by using this link: How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast | SpringerLink All conflicts of interest can be found online.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the...

This podcast is published open access in NETH and is fully citeable. You can access the original published podcast article through the NETH website and by using this link: https://link.springer.com/article/10.1007/s40120-023-00506-4  All conflicts of interest can be found online.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast...

 In this podcast, the authors summarize and highlight some of the T cell–redirecting bispecific antibodies (BsAb) currently in development for the treatment of relapsed/refractory multiple myeloma with a focus on the data reported at the oral session for BsAb at the American Society of Hematology’s 2022 meeting from clinical phase 1 and 2 studies. The six presentations reported the latest safety and efficacy data for the BsAb: talquetamab, elranatamab, teclistamab, forimtamig, and alnuctamab. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy...